These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 32424819)

  • 1. Clinicopathological characteristics and prognosis of amelanotic acral melanoma: A comparative study with pigmented acral melanoma.
    Gong HZ; Zheng HY; Li J
    Australas J Dermatol; 2020 Nov; 61(4):358-361. PubMed ID: 32424819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of clinicopathologic features and survival of histopathologically amelanotic and pigmented melanomas: a population-based study.
    Thomas NE; Kricker A; Waxweiler WT; Dillon PM; Busman KJ; From L; Groben PA; Armstrong BK; Anton-Culver H; Gruber SB; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Venn A; Kanetsky PA; Orlow I; Paine S; Ollila DW; Reiner AS; Luo L; Hao H; Frank JS; Begg CB; Berwick M;
    JAMA Dermatol; 2014 Dec; 150(12):1306-314. PubMed ID: 25162299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinically amelanotic or hypomelanotic melanoma: Anatomic distribution, risk factors, and survival.
    Wee E; Wolfe R; Mclean C; Kelly JW; Pan Y
    J Am Acad Dermatol; 2018 Oct; 79(4):645-651.e4. PubMed ID: 30241625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spatial transcriptomic analysis of amelanotic acral melanoma versus pigmented acral melanoma reveals distinct molecular determinants.
    Choi ME; Choi EJ; Lee JH; Won CH; Chang SE; Lee MW; Lee WJ
    Br J Dermatol; 2024 Sep; 191(4):580-591. PubMed ID: 38815138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regarding amelanotic melanomas.
    Shaw HM; Thompson JF
    Dermatol Surg; 1999 Nov; 25(11):918. PubMed ID: 10594617
    [No Abstract]   [Full Text] [Related]  

  • 6. Amelanotic melanoma.
    Gong HZ; Zheng HY; Li J
    Melanoma Res; 2019 Jun; 29(3):221-230. PubMed ID: 30672881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic features, delayed diagnosis, and survival in amelanotic acral melanoma: A comparative study with pigmented melanoma.
    Wu Q; Pan J; Lin W; Zhao S; Chen M; Lu L; Chen X; Su J
    J Am Acad Dermatol; 2024 Feb; 90(2):369-372. PubMed ID: 37690705
    [No Abstract]   [Full Text] [Related]  

  • 8. A rare case of acral amelanotic melanoma, nodular type.
    Mohammed Saeed D; Braniecki M; Groth JV
    Int Wound J; 2019 Dec; 16(6):1445-1449. PubMed ID: 31531925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic variables in patients with thick melanomas. Analysis of 362 cases.
    Aguilar-Romero E; Chávez-Hernández JD; Zepeda-Najar C; Salcedo-Hernández RA; Lino-Silva LS
    Gac Med Mex; 2021; 157(2):207-211. PubMed ID: 34270542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amelanotic melanomas presenting as red skin lesions: a diagnostic challenge with potentially lethal consequences.
    McClain SE; Mayo KB; Shada AL; Smolkin ME; Patterson JW; Slingluff CL
    Int J Dermatol; 2012 Apr; 51(4):420-6. PubMed ID: 22435430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matched analysis of the prognosis of amelanotic and pigmented melanoma in head and neck.
    Guo W; Yin G; Liu H; Duan H; Huang Z; Chen X
    Acta Otolaryngol; 2020 Sep; 140(9):785-788. PubMed ID: 32449432
    [No Abstract]   [Full Text] [Related]  

  • 12. Prognostic Significance of Subungual Anatomic Site in Acral Lentiginous Melanoma.
    Mejbel HA; Torres-Cabala CA; Milton DR; Ivan D; Nagarajan P; Curry JL; Ciurea AM; Rubin AI; Hwu WJ; Prieto VG; Aung PP
    Arch Pathol Lab Med; 2021 Aug; 145(8):943-952. PubMed ID: 33290520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amelanotic/hypomelanotic melanoma: clinical and dermoscopic features.
    Pizzichetta MA; Talamini R; Stanganelli I; Puddu P; Bono R; Argenziano G; Veronesi A; Trevisan G; Rabinovitz H; Soyer HP
    Br J Dermatol; 2004 Jun; 150(6):1117-24. PubMed ID: 15214897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pink enlarging plaque on the plantar foot: amelanotic acral lentiginous melanoma.
    Okhovat JP; Tahan SR; Kim CC
    Dermatol Online J; 2019 Jan; 25(1):. PubMed ID: 30710904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic, misdiagnosis, and survival differences between clinically amelanotic melanomas and pigmented melanomas.
    Strazzulla LC; Li X; Zhu K; Okhovat JP; Lee SJ; Kim CC
    J Am Acad Dermatol; 2019 May; 80(5):1292-1298. PubMed ID: 30654075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mohs micrographic surgery using HMB-45 for a recurrent acral melanoma.
    Griego RD; Zitelli JA
    Dermatol Surg; 1998 Sep; 24(9):1003-6. PubMed ID: 9754089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amelanotic acral melanomas: clinicopathological, BRAF mutation, and KIT aberration analyses.
    Choi YD; Chun SM; Jin SA; Lee JB; Yun SJ
    J Am Acad Dermatol; 2013 Nov; 69(5):700-707. PubMed ID: 23972510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spatial sequencing reveals transcriptional variation between amelanotic and pigmented acral melanoma.
    McMahon M; Deacon DC
    Br J Dermatol; 2024 Sep; 191(4):483-484. PubMed ID: 38878279
    [No Abstract]   [Full Text] [Related]  

  • 19. Amelanotic melanoma: a detailed morphologic analysis with clinicopathologic correlation of 75 cases.
    Cheung WL; Patel RR; Leonard A; Firoz B; Meehan SA
    J Cutan Pathol; 2012 Jan; 39(1):33-9. PubMed ID: 22050235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Incident Amelanotic Melanoma With Phenotypic Characteristics, MC1R Status, and Prior Amelanotic Melanoma.
    Vernali S; Waxweiler WT; Dillon PM; Kanetsky PA; Orlow I; Luo L; Busam KJ; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; Gallagher RP; Zanetti R; Rosso S; Sacchetto L; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Thomas NE;
    JAMA Dermatol; 2017 Oct; 153(10):1026-1031. PubMed ID: 28746718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.